🇺🇸 DTPa-IPV in United States

24 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 24

Most-reported reactions

1. Fallot^S Tetralogy — 3 reports (12.5%)
2. Foetal Exposure During Pregnancy — 3 reports (12.5%)
3. Hypersensitivity — 3 reports (12.5%)
4. Right Aortic Arch — 3 reports (12.5%)
5. Anaphylactic Reaction — 2 reports (8.33%)
6. Decreased Appetite — 2 reports (8.33%)
7. Pyrexia — 2 reports (8.33%)
8. Somnolence — 2 reports (8.33%)
9. Urticaria — 2 reports (8.33%)
10. Vomiting — 2 reports (8.33%)

Source database →

Frequently asked questions

Is DTPa-IPV approved in United States?

DTPa-IPV does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for DTPa-IPV in United States?

GlaxoSmithKline is the originator. The local marketing authorisation holder may differ — check the official source linked above.